Sarepta preps $1.2B war chest as DMD gene therapy nears accelerated FDA nod

Sprinting in an “urgent race against a brutal disease,” just like patients, Sarepta has raised a $1.2 billion war chest to prepare for a launch of the Duchenne muscular dystrophy gene therapy SRP-9001, which was filed for accelerated approval with the FDA during the third quarter.